Welcome to our dedicated page for Nanobiotix S.A. news (Ticker: NBTX), a resource for investors and traders seeking the latest updates and insights on Nanobiotix S.A. stock.
Nanobiotix S.A. (NBTX) news covers developments at a late-stage clinical biotechnology company that focuses on physics-based therapeutic approaches and nanotechnology platforms. As a dual-listed issuer on Euronext Paris and the Nasdaq Global Select Market, Nanobiotix regularly publishes updates that are relevant to investors following oncology-focused biotechnology and pharmaceutical preparation manufacturing.
Company news frequently highlights progress in the JNJ-1900 (NBTXR3) clinical program, including updates on the global Phase 3 NANORAY-312 study in locally advanced head and neck squamous cell cancers and Phase 1 and Phase 2 studies sponsored by Nanobiotix or The University of Texas MD Anderson Cancer Center. Releases may also describe regulatory designations, collaboration milestones with Janssen Pharmaceutica NV, and the transfer of sponsorship and operational control of key trials.
Another recurring theme in Nanobiotix news is the Curadigm Nanoprimer platform. The company reports on new patent applications, preclinical in vivo data, and Chemistry, Manufacturing, and Controls (CMC) activities, as well as material transfer agreements with biotechnology and pharmaceutical partners evaluating Nanoprimer combinations with intravenously administered therapeutics.
Investors can also find announcements related to capital markets activity, such as royalty-based financing agreements with HealthCare Royalty (HCRx), inclusion in the CAC Mid 60 and SBF 120 indices on Euronext Paris, and periodic disclosures on shares outstanding and voting rights under French regulations. In addition, Nanobiotix issues notices about participation in investor and healthcare conferences, where management presents the company’s strategy and clinical pipeline.
By following NBTX news, readers can track clinical, financial, and strategic updates that shape the company’s development trajectory and its work in oncology, drug bioavailability and biodistribution, and central nervous system disorder applications.
NANOBIOTIX (Euronext: NANO, NASDAQ: NBTX), a late-clinical stage biotechnology company, will announce its Q1 2024 financial and operational results on May 22, 2024, before US and EU markets open.
The announcement will be followed by a conference call and webcast at 8:00 am EDT / 2:00 pm CEST, featuring CEO Laurent Levy and CFO Bart van Rhijn, who will review the results and provide a business update.
The company's next Annual General Meeting (AGM) is scheduled for May 28, 2024, at its Paris headquarters. Meeting details and related documents are available on NANOBIOTIX's website.
NANOBIOTIX has announced that the US FDA has issued a Study May Proceed Letter for a new Phase 2 study evaluating NBTXR3 in patients with stage 3, unresectable non-small cell lung cancer (NSCLC). The study is sponsored by Johnson & Johnson Enterprise Innovation Inc., a subsidiary of Johnson & Johnson. This progress is part of Nanobiotix's global licensing agreement with Janssen Pharmaceutica NV, aimed at expanding the application of NBTXR3 to new cancer indications. The acceptance of this protocol by the FDA is seen as a significant step towards potentially providing improved treatment outcomes for a new group of cancer patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.